Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Seattle Genetics Reports Third Quarter 2019 Financial Results
October 29, 2019 4:02 PM EDT-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018-
-Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer Granted Priority Review by FDA; PDUFA Target Action Date March 15, 2020-
-Tucatinib HER2CLIMB Pivotal Trial Met Primary and Both Key Secondary Endpoints; New Drug Application to FDA Planned for the First Quarter of 2020-
-Conference Call Today at 4:30 p.m.... More
